CALL/AMGEN/400/0.1/21.06.24 | Real-time BOERSE MUENCHEN 07:56:09 28/05/2024 pm IST | ||
| 0.012 EUR | -20.00% |
|
| 3 months | -16.67% | ||
| 6 months | -65.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 0.012 | -20.00% |
| 27/24/27 | 0.015 | -11.76% |
| 24/24/24 | 0.017 | -19.05% |
| 23/24/23 | 0.021 | +23.53% |
| 22/24/22 | 0.017 | +6.25% |
Real-time BOERSE MUENCHEN
Last update May 28, 2024 at 07:56 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Goldman Sachs |
| WKN | GZ901B |
| ISIN | DE000GZ901B1 |
| Date issued | 20/02/2023 |
| Strike | 400 $ |
| Maturity | 21/06/2024 (24 Days) |
| Parity | 10 : 1 |
| Emission price | 0.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.193 € |
|---|---|
| Lowest since issue | 0.007 € |
| Spread | 0.03 € |
| Spread % | 71.43% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
305.8
USD
Average target price
316.3
USD
Spread / Average Target
+3.41%
- Stock Market
- Warrants
- Warrant
